TRT dosing mistakes: what doctors actually get wrong
Quick answer
Exogenous testosterone administration suppresses the HPG axis through negative feedback on the hypothalamus and pituitary, reducing endogenous LH secretion and Leydig cell testosterone production. This is established physiology, documented by Bhasin et al. (2001) and others, and means that naive supplementation strategies without accounting for this suppression can result in inadequate net androgen levels. Appropriate TRT dosing requires serial monitoring of total testosterone, free testosterone, LH, and FSH, not a one-time calculation of the apparent deficit.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @dr.randmcclain actually say?
McClain's argument is that doctors who dose testosterone based on a simple "make up the difference" math are making a physiological error. If you're at 400 ng/dL and your doctor wants you at 800, giving you just enough exogenous T to close that gap ignores the HPG axis. His claim: "your body is working on a thermostat" and the pituitary will simply reduce its own signaling, leaving you back at 400 or lower.
This is a specific, mechanistic claim about how the hypothalamic-pituitary-gonadal axis responds to exogenous testosterone administration. It's not vague wellness advice. It has a testable biological basis, and it's worth examining seriously rather than dismissing as influencer content.
Does the science back this up?
Largely, yes. The HPG axis suppression mechanism McClain describes is well-documented and not controversial in endocrinology. What he's describing is negative feedback: exogenous testosterone signals the hypothalamus and pituitary to reduce GnRH and LH secretion, which in turn suppresses endogenous testosterone production from the Leydig cells.
Bhasin et al. (2001, New England Journal of Medicine) demonstrated dose-dependent suppression of LH and endogenous testosterone when exogenous testosterone was administered to healthy men. The suppression wasn't partial or gentle. At doses typical of TRT, LH drops significantly. Shabsigh et al. (2005, Journal of Urology) similarly noted that men on TRT show measurable suppression of gonadotropins. The mechanism is not disputed. The clinical implication McClain draws, that underdosing leads to net-neutral or worse outcomes, follows logically from this physiology, though it's less directly studied as a standalone variable.
What did they get wrong (or right)?
He got the core biology right. The thermostat analogy is imprecise but not wrong. The HPG axis does operate through feedback loops that reduce endogenous production when circulating androgens rise, even modestly. Credit where it's due: this is a legitimate critique of naive dosing strategies that treat testosterone supplementation like adding water to a bucket.
What McClain glosses over is that this suppression is not always a problem requiring higher doses. The clinical goal of TRT is to reach a therapeutic level, not necessarily to preserve endogenous production. For men with primary hypogonadism, the testes aren't producing adequately regardless. For secondary hypogonadism, the suppression he describes is real but may still leave the patient at a clinically adequate total testosterone level if dosing is calibrated correctly over time. The claim that patients "drop back down to 400 or sometimes even less" is plausible but unsupported by a specific citation in his video, and the "or sometimes even less" framing leans toward alarm without hard data. Snyder et al. (2016, New England Journal of Medicine) showed that TRT can reliably raise testosterone levels when dosed appropriately, suggesting the suppression issue is manageable rather than inevitable.
What should you actually know?
The HPG axis suppression McClain describes is real physiology. Any doctor managing TRT should understand it. What this video doesn't tell you is that the clinical significance depends heavily on why you're on TRT in the first place, how your baseline LH and FSH looked, and what your treatment goals are.
If preserving fertility or endogenous function matters to you, there are co-administration strategies involving other medications that some clinicians use. That's a conversation between you and your prescribing physician, not a TikTok decision. The broader point, that dosing strategy matters and that a simplistic "fill the gap" approach can miss the mark, is valid. But "underdosing is a mistake" is not the same as "more is better," and McClain's framing risks pushing that implication without spelling out the risks of inappropriate dosing in the other direction.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT dosing mistakes: what doctors actually get wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT dosing mistakes: what doctors actually get wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Exogenous testosterone administration suppresses the HPG axis through negative feedback on the hypothalamus and pituitary, reducing endogenous LH secretion and Leydig cell testosterone production.
FormBlends verdict
Exogenous testosterone administration suppresses the HPG axis through negative feedback on the hypothalamus and pituitary, reducing endogenous LH secretion and Leydig cell testosterone production. This is established physiology, documented by Bhasin et al. (2001) and others, and means that naive supplementation strategies without accounting for this suppression can result in inadequate net androgen levels. Appropriate TRT dosing requires serial monitoring of total testosterone, free testosterone, LH, and FSH, not a one-time calculation of the apparent deficit.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Exogenous testosterone administration suppresses the HPG axis through negative feedback on the hypothalamus and pituitary, reducing endogenous LH secretion and Leydig cell testosterone production. This is established physiology, documented by Bhasin et al. (2001) and others, and means that naive supplementation strategies without accounting for this suppression can result in inadequate net androgen levels. Appropriate TRT dosing requires serial monitoring of total testosterone, free testosterone, LH, and FSH, not a one-time calculation of the apparent deficit.
- Exogenous testosterone suppresses LH secretion via HPG axis negative feedback, a mechanism confirmed in Bhasin et al. (2001, NEJM) and not clinically disputed.
- A simple gap-filling dosing approach that ignores this suppression can result in insufficient net testosterone levels, making the clinical critique in this video valid.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Exogenous testosterone suppresses LH secretion via HPG axis negative feedback, a mechanism confirmed in Bhasin et al. (2001, NEJM) and not clinically disputed.
- A simple gap-filling dosing approach that ignores this suppression can result in insufficient net testosterone levels, making the clinical critique in this video valid.
- Snyder et al. (2016, NEJM) demonstrated that iterative, monitored TRT dosing can reliably achieve target testosterone levels, suggesting suppression is manageable with proper protocol design.
- The degree of HPG suppression depends in part on the underlying cause of hypogonadism. Men with primary hypogonadism have less endogenous production to suppress than those with secondary hypogonadism.
- Falling below baseline testosterone after starting TRT, while mechanistically possible, is not universally documented and McClain does not cite data supporting the specific outcome he describes.
- Decisions about TRT dosing strategy, including whether to address HPG suppression or fertility preservation, require individualized evaluation and serial lab monitoring by a licensed clinician.
- The broader takeaway, that dosing strategy in TRT is not trivial and that the HPG axis must be considered, is clinically sound and worth patients understanding before starting therapy.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr. Rand McClain · TikTok creator
20.0K views on this video
The biggest mistake many doctors make in the TRT space. 👆🏼 #TRT #TestosteroneTherapy #HormoneOptimization #MensHealth #HealthAdvice
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr. Rand McClain, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.